(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.75%) $83.22
(-1.16%) $1.619
(-0.20%) $2 342.50
(-0.15%) $27.50
(0.51%) $926.80
(-0.09%) $0.934
(-0.01%) $11.02
(-0.15%) $0.799
(0.00%) $92.17
-0.38% SEK 103.70
Live Chart Being Loaded With Signals
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases...
Stats | |
---|---|
Dzisiejszy wolumen | 204 800 |
Średni wolumen | 201 179 |
Kapitalizacja rynkowa | 5.57B |
EPS | SEK0 ( 2024-02-20 ) |
Następna data zysków | ( SEK-1.240 ) 2024-05-06 |
Last Dividend | SEK0 ( N/A ) |
Next Dividend | SEK0 ( N/A ) |
P/E | -11.93 |
ATR14 | SEK0.251 (0.24%) |
Wolumen Korelacja
Calliditas Therapeutics Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Calliditas Therapeutics Korelacja - Waluta/Towar
Calliditas Therapeutics Finanse
Annual | 2023 |
Przychody: | SEK1.21B |
Zysk brutto: | SEK1.13B (93.62 %) |
EPS: | SEK-8.69 |
FY | 2023 |
Przychody: | SEK1.21B |
Zysk brutto: | SEK1.13B (93.62 %) |
EPS: | SEK-8.69 |
FY | 2023 |
Przychody: | SEK0 |
Zysk brutto: | SEK0 (0.00 %) |
EPS: | SEK0 |
FY | 2022 |
Przychody: | SEK802.88M |
Zysk brutto: | SEK787.68M (98.11 %) |
EPS: | SEK-7.78 |
Financial Reports:
No articles found.
Calliditas Therapeutics
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej